menu
    • menu
    [{"orgOrder":0,"company":"Akers Biosciences","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Akers Biosciences \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Akers Biosciences \/ MyMD Pharmaceuticals"},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"Premas Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRAK-03202 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Akers Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Akers Biosciences \/ Premas Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Akers Biosciences \/ Premas Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Akers Biosciences

    Menu

    Akers Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Akers Biosciences

                            U.S.A arrow
                            Arvo
                            Not Confirmed

                            Akers Biosciences

                            U.S.A arrow
                            Arvo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : MyMD Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement

                            Details : Following the merger, the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets, including MYMD-1, a novel drug being developed to treat autoimmune and age-related diseases, including exten...

                            Product Name : MYMD-1

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 11, 2020

                            Lead Product(s) : Isomyosamine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : MyMD Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Akers Biosciences

                            U.S.A arrow
                            AAPS National Biotech
                            Not Confirmed

                            Akers Biosciences

                            U.S.A arrow
                            AAPS National Biotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRAK-03202 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Premas Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Akers, Premas Note Positive Proof-Of-Concept Data of Covid-19 Vaccine

                            Details : SARS CoV-2 met both the primary endpoints, safety and immune response. The vaccine candidate was safe even at higher doses and generated a robust immune response against the three SARS-Cov2 antigens.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 27, 2020

                            Lead Product(s) : PRAK-03202 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Premas Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth